1.Llovet JM, Burroughs A, Bruix J: Hepatocellular carcinoma. Lancet 2003, 362(9399):1907–1917.
2.Bosch FX, Ribes J, Diaz M, Cleries R: Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004, 127(5 Suppl 1):S5-S16.
3.Hao XS, Wang PP, Chen KX, Li Q, He M, Yu SB, Guo ZY, Perruccio A, Rohan T: Twenty-year trends of primary liver cancer incidence rates in an urban Chinese population. Eur J Cancer Prev 2003, 12(4):273–279.
4.Chen CJ, Iloeje UH, Yang HI: Long-term outcomes in hepatitis B: the REVEAL-HBV study. Clin Liver Dis 2007, 11(4):797–816, viii.
5.Schmidt N, Neumann-Haefelin C, Thimme R: Cellular immune responses to hepatocellular carcinoma: lessons for immunotherapy. Dig Dis 2012, 30(5):483–491.
6.Schmidt J, Blum HE, Thimme R: T-cell responses in hepatitis B and C virus infection: similarities and differences. Emerg Microbes Infect 2013, 2(3):e15.
7.Marshall NB, Swain SL: Cytotoxic CD4 T cells in antiviral immunity. J Biomed Biotechnol 2011, 2011:954602.
8.Quezada SA, Simpson TR, Peggs KS, Merghoub T, Vider J, Fan X, Blasberg R, Yagita H, Muranski P, Antony PA et al: Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med 2010, 207(3):637–650.
9.Fu J, Zhang Z, Zhou L, Qi Z, Xing S, Lv J, Shi J, Fu B, Liu Z, Zhang JY et al: Impairment of CD4+ cytotoxic T cells predicts poor survival and high recurrence rates in patients with hepatocellular carcinoma. Hepatology 2013, 58(1):139–149.
10.Subramaniam A, Shanmugam MK, Perumal E, Li F, Nachiyappan A, Dai X, Swamy SN, Ahn KS, Kumar AP, Tan BK et al: Potential role of signal transducer and activator of transcription (STAT)3 signaling pathway in inflammation, survival, proliferation and invasion of hepatocellular carcinoma. Biochim Biophys Acta 2013, 1835(1):46–60.
11.Lin HY, Chiang CH, Hung WC: STAT3 upregulates miR–92a to inhibit RECK expression and to promote invasiveness of lung cancer cells. Br J Cancer 2013, 109(3):731–738.
12.Ren L, Wang X, Dong Z, Liu J, Zhang S: Bone metastasis from breast cancer involves elevated IL–11 expression and the gp130/STAT3 pathway. Med Oncol 2013, 30(3):634.
13.Cho KH, Jeong KJ, Shin SC, Kang J, Park CG, Lee HY: STAT3 mediates TGF-beta1-induced TWIST1 expression and prostate cancer invasion. Cancer Lett 2013, 336(1):167–173.
14.Lesinski GB: The potential for targeting the STAT3 pathway as a novel therapy for melanoma. Future Oncol 2013, 9(7):925–927.
15.Liu Y, Fuchs J, Li C, Lin J: IL–6, a risk factor for hepatocellular carcinoma: FLLL32 inhibits IL–6-induced STAT3 phosphorylation in human hepatocellular cancer cells. Cell Cycle 2010, 9(17):3423–3427.
16.Tai WT, Shiau CW, Chen HL, Liu CY, Lin CS, Cheng AL, Chen PJ, Chen KF: Mcl–1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC–59 in hepatocellular carcinoma cells. Cell Death Dis 2013, 4:e485.
17.Wang X, Xin W, Zhang H, Zhang F, Gao M, Yuan L, Xu X, Hu X, Zhao M: Aberrant expression of p-STAT3 in peripheral blood CD4+ and CD8+ T cells related to hepatocellular carcinoma development. Mol Med Rep 2014, 10(5):2649–2656.
18.Moss RW: Patient perspectives: Tijuana cancer clinics in the post-NAFTA era. Integr Cancer Ther 2005, 4(1):65–86.
19.Saleem M, Asif J, Asif M, Saleem U: Amygdalin, from Apricot Kernels, Induces Apoptosis and Causes Cell Cycle Arrest in Cancer Cells: An Updated Review. Anticancer Agents Med Chem 2018.
20.Jaswal V, Palanivelu J, C R: Effects of the Gut microbiota on Amygdalin and its use as an anti-cancer therapy: Substantial review on the key components involved in altering dose efficacy and toxicity. Biochem Biophys Rep 2018, 14:125–132.
21.Abboud MM, Al Awaida W, Alkhateeb HH, Abu-Ayyad AN: Antitumor Action of Amygdalin on Human Breast Cancer Cells by Selective Sensitization to Oxidative Stress. Nutr Cancer 2018:1–8.
22.Makarevic J, Tsaur I, Juengel E, Borgmann H, Nelson K, Thomas C, Bartsch G, Haferkamp A, Blaheta RA: Amygdalin delays cell cycle progression and blocks growth of prostate cancer cells in vitro. Life Sci 2016, 147:137–142.
23.Qian L, Xie B, Wang Y, Qian J: Amygdalin-mediated inhibition of non-small cell lung cancer cell invasion in vitro. Int J Clin Exp Pathol 2015, 8(5):5363–5370.
24.Tang F, Fan K, Wang K, Bian C: Amygdalin attenuates acute liver injury induced by D-galactosamine and lipopolysaccharide by regulating the NLRP3, NF-kappaB and Nrf2/NQO1 signalling pathways. Biomed Pharmacother 2018, 111:527–536.
25.Hwang HJ, Lee HJ, Kim CJ, Shim I, Hahm DH: Inhibitory effect of amygdalin on lipopolysaccharide-inducible TNF-alpha and IL–1beta mRNA expression and carrageenan-induced rat arthritis. J Microbiol Biotechnol 2008, 18(10):1641–1647.
26.Zhang A, Pan W, Lv J, Wu H: Protective Effect of Amygdalin on LPS-Induced Acute Lung Injury by Inhibiting NF-kappaB and NLRP3 Signaling Pathways. Inflammation 2017, 40(3):745–751.
27.Buritova J, Chapman V, Honore P, Besson JM: The contribution of peripheral bradykinin B2 receptors to carrageenan-evoked oedema and spinal c-Fos expression in rats. Eur J Pharmacol 1997, 320(1):73–80.
28.Liu Y, Wang Y, He X, Zhang S, Wang K, Wu H, Chen L: LncRNA TINCR/miR–31–5p/C/EBP-alpha feedback loop modulates the adipogenic differentiation process in human adipose tissue-derived mesenchymal stem cells. Stem Cell Res 2018, 32:35–42.
29.Yang PL, Althage A, Chung J, Maier H, Wieland S, Isogawa M, Chisari FV: Immune effectors required for hepatitis B virus clearance. Proc Natl Acad Sci U S A 2010, 107(2):798–802.
30.Zhang H, Hou X, Cai H, Zhuang X: Effects of microwave ablation on T-cell subsets and cytokines of patients with hepatocellular carcinoma. Minim Invasive Ther Allied Technol 2017, 26(4):207–211.
31.Mantovani A, Allavena P, Sica A, Balkwill F: Cancer-related inflammation. Nature 2008, 454(7203):436–444.
32.Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Pilon-Thomas S, Niu G, Kay H, Mule J, Kerr WG et al: Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 2005, 11(12):1314–1321.
33.Iorio R, Frisullo G, Nociti V, Patanella KA, Bianco A, Marti A, Mirabella M, Tonali PA, Batocchi AP: T-bet, pSTAT1 and pSTAT3 expression in peripheral blood mononuclear cells during pregnancy correlates with post-partum activation of multiple sclerosis. Clin Immunol 2009, 131(1):70–83.
34.Behboudi S, Boswell S, Williams R: Cell-mediated immune responses to alpha-fetoprotein and other antigens in hepatocellular carcinoma. Liver Int 2010, 30(4):521–526.